XML 91 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share-Based Compensation (Notes)
 12 Months Ended
Dec. 31, 2012
Share-based Compensation [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock.  The following table summarizes the components of share-based compensation expense for the years ended December 31, 2012 and 2011 (in thousands):
 
Year Ended December 31,
 
2012
 
2011
Cost of goods sold
$
195.0

 
$
96.9

Research and development
432.9

 
867.8

Selling, general and administrative
6,084.6

 
9,301.3

Total share-based compensation expense
$
6,712.5

 
$
10,266.0

 
 
 
 


Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2012 were as follows (dollars in thousands):
 
Stock Options
 
Warrants
 
Restricted Stock
Unrecognized compensation cost
$
1,620.1

 
$
20.5

 
$
143.0

Expected weighted-average period in years of compensation cost to be recognized
1.68

 
0.44

 
0.19



Total fair value of shares vested and the weighted average estimated fair values of shares grant for the years ended December 31, 2012 and 2011 were as follows (dollars in thousands):
 
 
Stock Options
 
Warrants
 
 
Year Ended December 31,
 
Year Ended December 31,
 
 
2012
 
2011
 
2012
 
2011
Total fair value of shares vested
 
$
5,408.0

 
$
6,194.1

 
$
171.6

 
$
269.1

Weighted average estimated fair value of shares granted
 
0.36

 
1.06

 
0.41

 
0.74



On April 4, 2011, the Company entered into an amendment of its May 26, 2006 employment agreement with Dr. Robin L. Smith, pursuant to which, as previously amended (the “Agreement”), Dr. Smith serves as Chairman of the Board and Chief Executive Officer of the Company. Pursuant to the amendment, among other things, Dr. Smith was granted an option to purchase 1,500,000 shares of Common Stock at a per share exercise price equal to the closing price of the Common Stock on the date of the amendment, with 500,000 shares vesting on each of the date of grant, December 31, 2011 and December 31, 2012; all other unvested options held by Dr. Smith were immediately vested, and any vested options previously or hereafter granted to Dr. Smith during the remainder of the term shall remain exercisable following termination of employment for the full option term until the expiration date. Pursuant to the modification on April 4, 2011 of Dr. Smith’s stock options, the Company recognized $722,900 of incremental compensation cost during the twelve months ended December 31, 2011. On November 13, 2012, the Company further amended the Agreement pursuant to which all unvested options immediately vested. This modification did not result in additional incremental compensation cost.
 
Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:
 
 
Stock Options
 
Warrants
 
 
Year Ended December 31,
 
Year Ended December 31,
 
 
2012
 
2011
 
2012
 
2011
Expected term - minimum (in years)
 
2
 
3
 
2
 
3
Expected term - maximum (in years)
 
10
 
10
 
5
 
5
Expected volatility - minimum
 
73%
 
79%
 
76%
 
80%
Expected volatility - maximum
 
84%
 
85%
 
83%
 
86%
Expected dividend yield
 
—
 
—
 
—
 
—
Risk-free interest rate - minimum
 
0.28%
 
0.40%
 
0.27%
 
0.78%
Risk-free interest rate - maximum
 
1.99%
 
3.45%
 
0.88%
 
2.19%